# Oxford Biomedica PLC (OXB.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Biotechnology. Price 465p, market value 562 millionp.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Oxford Biomedica PLC reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Price / book: 6.1×**. The shares trade at 6.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -12.2%** (5-yr avg -0.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 39.9%**. Oxford Biomedica PLC keeps 39.9% of revenue after the direct cost of what it sells.
- **Operating margin: -24.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -17.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -33.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -50.0%**. Return on all capital, debt included, is -50.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -22.5%**. Each dollar of assets produces -22.5% of profit.

## Growth
- **Revenue growth (1 yr): 31.0%** (3-yr 6.4%/yr, 5-yr 14.0%/yr). Revenue grew 31.0% over the last year, against 14.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 35.7%**. Earnings per share rose 35.7%, roughly in step with revenue.

## Financial health
- **Debt to equity: 1.62**. Debt is 1.62 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Oxford Biomedica PLC holds more cash than debt.
- **Interest coverage: -3.0×**. Operating profit covers interest only -3.0×: fragile.
- **Current ratio: 2.20** (quick 2.00). Current assets cover the next year's liabilities 2.20 times.
- **Altman Z-score: 2.41**. A Z-score of 2.41 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Oxford Biomedica PLC does not currently pay a dividend, but it returned -13.4% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover Oxford Biomedica PLC; the consensus is buy, with an average price target of 712p (+53% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -25.7%** (YTD -28.8%, 3-mo -29.7%). The shares are down 25.7% over twelve months including dividends.
- **From 52-week high: -51.7%** (10.6% above the low). Trading 52% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 33**. An RSI of 33 is neutral.
- **Beta (1 yr): 1.09** (volatility 52%). Beta of 1.09 against the FTSE All-Share: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OXB.L · Page: https://foliofundamentals.com/stocks/oxb.l

Not investment advice.